Résumé
Abstract 921
- Titre
- Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia
- Créateurs - sans rôle
- William G. Wierda - Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, TX, USAThomas J. Kipps - University of California San DiegoJiri Mayer - University Hospital BrnoTadeusz Robak - Medical University of LodzMartin JS Dyer - MRC Toxicology Unit, Leicester University, Leicester, United KingdomRichard R. Furman - Weill Cornell Medical College, New York, NY, USAPeter Hillmen - St James's University HospitalStephan Stilgenbauer - Universität UlmCatherine D. Williams - Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United KingdomMarek Trneny - Charles UniversityGuillaume Cartron - Hôpital Saint EloiFrancisco J. Hernandez-Ilizaliturri - Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USASwaminathan Padmanabhan - Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USAGeoffrey W. Chan - GlaxoSmithKline, Collegeville, PA, USAIra V. Gupta - GlaxoSmithKline, Collegeville, PA, USAMichele M. Gorczyca - GlaxoSmithKline, Collegeville, PA, USARandy L. Davis - GlaxoSmithKline, Research Triangle Park, NC, USANedjad Losic - Genmab A/S, Copenhagen K, DenmarkSteen Lisby - Genmab, Copenhagen, DenmarkAnders Österborg - Dept of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden
- Détails de publication
- Blood, Vol.116(21), pp.921-921
- Nombre de pages
- 1
- Identifiants
- 99139767309311
- Unité académique
- Institut de Génétique Moléculaire de Montpellier - IGMM
- Langue
- English
- Type de ressource
- Journal article